Literature DB >> 22959192

Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.

Alberto Briganti1, Martin Spahn, Steven Joniau, Paolo Gontero, Marco Bianchi, Burkhard Kneitz, Felix K H Chun, Maxine Sun, Markus Graefen, Firas Abdollah, Giansilvio Marchioro, Detlef Frohenberg, Simone Giona, Bruno Frea, Pierre I Karakiewicz, Francesco Montorsi, Hein Van Poppel, R Jeffrey Karnes.   

Abstract

BACKGROUND: Survival after surgical treatment using competing-risk analysis has been previously examined in patients with prostate cancer (PCa). However, the combined effect of age and comorbidities has not been assessed in patients with high-risk PCa who might have heterogeneous rates of competing mortality despite the presence of aggressive disease.
OBJECTIVE: To examine the risk of 10-yr cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathologic characteristics of patients treated with radical prostatectomy (RP) for high-risk PCa. DESIGN, SETTING, AND PARTICIPANTS: Within a multi-institutional cohort, 3828 men treated with RP for high-risk PCa (defined as the presence of at least one of these risk factors: prostate-specific antigen >20 ng/ml, biopsy Gleason score 8-10, clinical stage ≥ T3) were identified. INTERVENTION: All patients underwent RP and pelvic lymph node dissection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Competing-risk Poisson regression analyses were performed to simultaneously assess the 10-yr CSM and OCM rates after RP. The same analyses were also conducted after stratification of patients according to age at surgery, comorbidity status assessed by the Charlson Comorbidity Index (CCI), and number of risk factors (one vs two or more). RESULTS AND LIMITATIONS: Overall, 229 patients (5.9%) died from PCa; 549 (14.3%) died from other causes. The 10-yr CSM and OCM rates ranged from 5.1% to 12.8% and from 4.3% to 37.4%, respectively. Age and CCI were the major determinants of OCM; their impact on CSM was minimal. OCM was the leading cause of death in all patient groups except in young men (≤ 59 yr) with no comorbidities, regardless of the number of risk factors (10-yr CSM and OCM 6.9-12.8% and 5.5-6.3%, respectively). The main limitation was the lack of patients managed conservatively.
CONCLUSIONS: Even in the context of high-risk PCa, long-term CSM after RP is modest and represents the leading cause of death only in young, healthy patients. Conversely, older and sicker patients with multiple risk factors are at the highest risk of dying from OCM while sharing very low CSM rates.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22959192     DOI: 10.1016/j.eururo.2012.08.054

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  26 in total

1.  Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.

Authors:  Joo Yong Lee; Ho Won Kang; Koon Ho Rha; Nam Hoon Cho; Young Deuk Choi; Sung Joon Hong; Kang Su Cho
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-12       Impact factor: 4.553

Review 2.  Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.

Authors:  Fouad Aoun; Ali Bourgi; Elias Ayoub; Elie El Rassy; Roland van Velthoven; Alexandre Peltier
Journal:  Ther Adv Urol       Date:  2017-03-01

3.  Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.

Authors:  I Henríquez; A Rodríguez-Antolín; J Cassinello; C Gonzalez San Segundo; M Unda; E Gallardo; J López-Torrecilla; A Juarez; J Arranz
Journal:  Clin Transl Oncol       Date:  2017-08-07       Impact factor: 3.405

4.  ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.

Authors:  K-C Huang; M Dolph; B Donnelly; T A Bismar
Journal:  Clin Transl Oncol       Date:  2014-05-06       Impact factor: 3.405

5.  Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy.

Authors:  A Sivaraman; G Ordaz Jurado; X Cathelineau; Eric Barret; P Dell'Oglio; S Joniau; M Bianchi; A Briganti; M Spahn; P Bastian; J Chun; P Chlosta; P Gontero; M Graefen; R Jeffrey Karnes; G Marchioro; B Tombal; L Tosco; H Henk van der Poel; R Sanchez-Salas
Journal:  World J Urol       Date:  2016-02-20       Impact factor: 4.226

6.  Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort study.

Authors:  Massimo Valerio; Yannick Cerantola; Urs Fritschi; Martin Hubner; Katia Iglesias; Anne-Sophie Legris; Ilaria Lucca; Yannis Vlamopoulos; Laurent Vaucher; Patrice Jichlinski
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

7.  Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.

Authors:  F Moltzahn; J Karnes; P Gontero; B Kneitz; B Tombal; P Bader; A Briganti; F Montorsi; H Van Poppel; S Joniau; M Spahn
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-12-23       Impact factor: 5.554

Review 8.  [Multimodal therapy of locally advanced prostate cancer].

Authors:  A Heidenreich; D Böhmer
Journal:  Urologe A       Date:  2016-03       Impact factor: 0.639

9.  Impact of comorbidities at diagnosis on prostate cancer treatment and survival.

Authors:  Katarina Luise Matthes; Manuela Limam; Giulia Pestoni; Leonhard Held; Dimitri Korol; Sabine Rohrmann
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-07       Impact factor: 4.553

Review 10.  Surgical management of high-risk, localized prostate cancer.

Authors:  Lamont J Wilkins; Jeffrey J Tosoian; Debasish Sundi; Ashley E Ross; Dominic Grimberg; Eric A Klein; Brian F Chapin; Yaw A Nyame
Journal:  Nat Rev Urol       Date:  2020-11-10       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.